Judge rules Florida's ban on gender-affirming care for minors unconstitutional; first consensus definition for long COVID aims to standardize diagnosis and care; pilot program for clinical trial diversity discontinued due to high cost and lack of impact.
A federal judge has ruled that Florida's new restrictions on gender-affirming treatments for minors are unconstitutional, asserting that the legislation promoted by Governor Ron DeSantis and other Republican lawmakers discriminates against transgender individuals, according to Politico. The decision marks a significant victory for human rights groups who argued that the ban violated equal protection rights. However, Florida plans to appeal the ruling, maintaining that the restrictions are necessary for protecting children from irreversible harm.
The National Academies of Sciences, Engineering, and Medicine (NASEM) have published a new consensus definition for long COVID, addressing the need for a unified diagnosis framework, according to CIDRAP. The definition describes long COVID as a chronic condition associated with SARS-CoV-2 infection that persists for at least 3 months and affects 1 or more organ systems. This standardization aims to enhance research, diagnosis, and care for the millions affected by long COVID.
The National Cancer Institute (NCI) piloted a program to cover travel expenses for patients with cancer and their caregivers to attend clinical trial screenings, aiming to attract a more diverse group of volunteers, according to Stat. Despite this effort, the program was discontinued after a year due to high costs and no significant increase in participant diversity. The initiative coincided with budget cuts, highlighting the challenges of enrolling diverse populations in clinical research.
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More